

CONTENTS

List of contents	Page
* LIST OF TABLES	III
* LIST OF HISTORGRAMS	V
* LIST OF FIGURES	VI
* LIST OF APPENDICES	VIII
* LIST OF ABBREVIATIONS	VIII
* INTRODUCTION	1
* AIM OF THE WORK	3
* REVIEW OF LITERATURE	4
• Rheumatoid Arthritis (RA):	4
- <i>Epidemiology of RA.</i>	6
- <i>Etiology of RA.</i>	17
- <i>Pathology of RA.</i>	20
- <i>Pathogenesis of RA.</i>	26
- <i>Clinical aspects of RA.</i>	47
- <i>Diagnosis of RA.</i>	50
- <i>Assessment of RA.</i>	61
- <i>Investigations of RA.</i>	

-Differential diagnosis of RA.	71
- Management of RA.	73
• Power Doppler Ultrasonography(PDUS):	91
- Introduction of PDUS.	91
- Doppler instruments.	94
- Techniques of PDUS .	100
- General principal of PDUS .	102
- Role of PDUS in rheumatology.	104
- Doppler-artifacts.	112
* PATIENTS AND METHODS.	115
* RESULTS.	130
* DISCUSSION.	162
* SUMMARY AND CONCLUSIONS.	174
*APPENDICES.	181
* REFERENCES.	183
* ARABIC SUMMARY.	٦-١

LIST OF TABLES

List of Tables	Page
<u>Tables of Review of Literature</u>	
Table (1): Infectious agents reported to trigger rheumatoid arthritis.	12
Table (2): criteria of RA.	47
Table(3): new criteria of RA.	48
Table (4): Modified Larsen score.	58
<u>Tables of Results</u>	
Table (1): Demographic, clinical and laboratory data of the patients.	137
Table (2): Age distribution in the studied groups.	138
Table (3): Sex distribution in the studied groups.	138
Table(4): Comparison between the mean of different clinical variables of patients (group I and group II) .	139
Table(5): Comparison between the mean of and laboratory variables of patients (group I and group II.	140
Table(6): comparison between the seropositivity in patients (group I and group II).	141
Table(7): comparsion between PDUS grading in patient (group I and group II).	143
Table(8): Comparison between the mean of PDUS variables in patients (group I and group II).	147
Table(9): Comparison between the mean of PDUS variables in group I patients (moderate and high disease activity	

subgroups).	148
Table(10): Comparison between the mean of PDUS variables in group II patients (Remission and low disease activity subgroups).	150
Table(11): Comparison between different PDUS grades as regard functional capacity in group I patient.	152
Table(12): Comparison between different PDUS grades as regard functional capacity in group II patient.	153
Table(13): Comparison between different PDUS grades as regard laboratory variables in group I patient.	154
Table(14): Comparison between different PDUS grades as regard laboratory variables in group II patient.	155
Table(15): Comparison between different PDUS grades regarding seropositivity in group I patient.	156
Table(16): Comparison between different PDUS grades regarding seropositivity in group II patient.	157
Table(17): comparison between different grades of radiological severity in group I patient as regards PDUS variables.	158
Table(18): comparsion between different grades of radiological severity in group II patient as regards PDUS variables.	159
Table(19): Correlation coefficients of RA disease variables vs PDUS variables in all patients (group I and group II).	160

LIST OF HISTOGRAMS

List of histograms	Page
Histogram(1): The mean different clinical variables of patients (group I and group II).	139
Histogram(2): The mean of the laboratory variables of patients (group I and group II).	140
Histogram(3): Incidence of seropositivity in patients (group I and group II).	141
Histogram(4): PDUS grading in patient (group I and group II).	143
Histogram(5): PDUS grading among group I patients.	144
Histogram(6): PDUS grading among group II patients.	144
Histogram(7): The mean of PDUS variables in patients (group I and group II).	147
Histogram(8): Group I subgroups (Moderate, High disease activity).	148
Histogram(9): The mean of PDUS variables in group I patients (moderate and high disease activity subgroups).	149
Histogram(10): Group II subgroups (remission, low disease activity).	150
Histogram(11): The mean of PDUS variables in group II patients (Remission and low disease activity subgroups).	151
Histogram(12): Different PDUS grades as regard functional capacity in group I patient.	152
Histogram(13): Different PDUS grades as regard functional capacity in group II patient.	153

Histogram(14): Different PDUS grades as regard laboratory variables in group I patient.	154
Histogram(15): Different PDUS grades as regard laboratory variables in group II patient.	155
Histogram(16): Different PDUS grades regarding seropositivity in group I patient.	156
Histogram(17): Different PDUS grades regarding seropositivity in group II patient.	157
Histogram(18): Different grades of radiological severity in group I patient as regards PDUS variables.	158
Histogram(19): Different grades of radiological severity in group II patient as regards PDUS variables.	159
Histogram(20): Correlation between RI and DAS28.	161
Histogram(21): Correlation between CFS and DAS28.	161

LIST OF FIGURES

List of figures	Page
<p style="text-align: center;">Figures of Review of Literature</p> <hr/> <p>Fig.(1) : View of the difference between a normal joint and a joint affected by rheumatoid arthritis. The synovial fluid changes in the figure from the top to the bottom. The darkened jagged-edge mass is the inflammation caused by various factor of RA.</p>	24

Fig.(2): rheumatoid hand.	27
<p style="text-align: center;">Figures of Patients and Methods</p> <hr/>	
Fig.(1) : Power Doppler Ultrasound apparatus.(high-resolution equipment (Voluson Pro v, General electric) using 5 to 9 MHz multifrequency matrix array linear transducers.	123
Fig.(2): . Method of application of PDUS to MCPs joints.	124
Fig. (3): Method of application of PDUS to ulnocarpal joint.	124
Fig. (4): Method of application of PDUS to radiocarpal joint.	125
<p style="text-align: center;">Figures of Results</p> <hr/>	
Fig. (1): X-ray of rheumatoid hand (patient in early change).	142
Fig.(2): PDUS grade 0 of metacarpophalangeal joint in RA patient with low disease activity (group II).	145
Fig.(3): PDUS grade 1 of metacarpophalangeal joint in RA patient with remission (group II).	145
Fig.(4): PDUS grade 2 of radiocarpal joint in RA patient with low disease activity (group II).	146
Fig.(5): PDUS grade3 of metacarpophalangeal joint in RA patient with high disease activity (group I).	146

LIST OF APPENDICES

List of Appendices	Page
Appendix (1): Stanford Health Assessment Questionnaire.	229-230

LIST OF ABBREVIATIONS

3DUS	Three-dimensional ultrasonography.
ACPAs	anti-cyclic citrullinated peptide antibodies.
ACR	American College of Rheumatology.
AIMS	Arthritis Impact Measurement Scales
ANAs	Antinuclear Antibodies.
ARA	American Rheumatology Association
A-SAA	acute phase serum amyloid A protein.
AZA	Azathioprine.
B cell	B lymphocyte.
BOOP	Bronchiolitis obliterans with organizing pneumonia.

BOOP	Bronchiolitis obliterans with organizing pneumonia.
C 2	Cervical spine 2.
C1	Cervical spine 1
CD	Color Doppler.
CePD	Contrast-enhanced Power Doppler .
CFD	color flow Doppler.
CFS	flow signal score .
cm	Centimeters
COX	Cyclooxygenase.
COX-2	cyclo-oxygenase-2 .
CR	Compared Conventional radiography.
CRP	C-reactive protein .
CT	Computed Tomography.
CT	Computed tomography
CW	Continuous wave
DAS 28	Disease activity score 28.
DIP	distal interphalangeal (DIP)joints.
DMARDs	disease-modifying antirheumatic drugs .
EBV	Epstein-Barr virus.

ECU	extensor carpi ulnaris.
ELISA	enzyme-linked immunosorbent assays.
ESR	erythrocyte sedimentation rate.
EULAR	European League Against Rheumatism
FS	Felty's syndrome.
GD	gadolinium compound
GN	Glomerulonephritis.
HCQ	hydroxychloroquine
Hep.C	Hepatitis C
HIV	Human immune deficiency virus
HLA-DRB1	Human leucocyte antigen
HRT	Hormone replacement therapy.
HRT	Hormone replacement therapy.
Ig(A, G ,M)	Immunoglobulin (A,G,M).
IL-(1,2,6,8,10)	Inter-Leukin (1,2,6,8,10).
IL-1	Interleukin-1 genes.
IL-1 Ra	Inter-Leukin-1 Receptor antagonist.
IL-1β	Inter-Leukin-1 Beta.
ILAR/WHO	International League of associations for Rheumatology/World Health Organization .

kCS	Keratoconjunctivitis sicca.
kCS	Keratoconjunctivitis sicca.
kg	Kilogram.
LDH	lactic dehydrogenase.
LT-α	lymphotoxin- α .
m/sec	Meter/ second.
MCP	metacarpophalangeal joints.
mg	Milligram.
MHC	Major histocompatibility.
MHz	Megahertz.
MLS	Modified Larsen score
mm³	Millimeter ³ .
MMP	matrix metalloproteinase.
MMP	matrix metalloproteinase.
MRI	Magnetic resonance images.
msec	Millisecond.
MSUS	Musculoskeletal ultrasound .
MTP	Metatarsophalangeal joint.
MTX	Methotrexate.

NSAIDs	Non-steroidal anti-inflammatory.
OMIRACT	Outcome Measures in Rheumatoid Arthritis Clinical Trials.
PAN	Panarthrititis nodosa.
PCR	Polymerase Chain Reaction.
PDUS	Power Doppler sonography
PG	Prostaglandine.
PG(E2)	Prostaglandin (E2).
PIP	interphalangeal (PIP) joints.
PIP	Proximal Interphalangeal joint.
PsA	Psoriatic arthritis
PW	Pulsed Wave.
R	Receptor.
RA	Rheumatoid arthritis .
RBCs	red blood cells.
RF	rheumatoid factor.
RI	resistive index.
SCC	squamous cell carcinoma.
SLE	systemic lupus erythematosus.
SSZ	Salazopyrine.

T cell	T lymphocyte.
TCDD	tetrachlorodibenzo-P-dioxin.
TCR	T cell receptor.
TCZ	Tocilizumab.
TENS	transcutaneous electrical nerve stimulation.
Th1	T-helper 1.
TMJ	temporomandibular joint.
TNF-R	Tumour Necrosis Factor-Receptor.
TNF-α	tumor necrosis factor- α .
UDPGD	Uridine Diphosphoglucose Dehydrogenase.
US	Ultrasound.
V	velocity determination .
VAS	visual analogue scale.
VEGF	Vascular endothelial growth factor.
vs	Versus.
θ	Theta.